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delayed among nonmyeloablative recipients (p=O.O2), 
presumably a result of the initial mixed host/donor 
lymphoid chimerism. Most HLA-matched related 
recipients had stable engraftment despite using only 2 
Gy TBI conditioning. An initially observed 17% graft 
rejection rate was reduced to 3% by the addition of 
three doses of Audarabine immediately preceding TBI. 
This has allowed sustained engraftment also with HLA- 
identical unrelated HSCT. Approximately half of the 
patients experienced acute GVHD. Though GVHD 
appeared mostly to be of moderate severity, we 
extended the period of postgrafting immunosuppression 
from 35 days to now a minimum of 84 days after 
transplant in order to reduce the risk of GVHD. The 
optimal duration of postgrafting immunosuppression 
still remains to be determined. The initially observed 
mixed donor-host hematopoietic chimerism was un- 
stable in most patients, progressing to full-donor 
chimerism. Impressive antitumor responses have been 
seen with complete remissions in 66% of those patients 
who had measurable disease before transplant. Of note, 
attainment of complete remission might take months, 
and in some cases, exceeded 1 year. The durability of 
these remissions is still unknown given that the longest 
follow-up is only 4 years. The nonmyeloablative trans- 
plant approach has now also been successfully applied 
to patients with nonmalignant diseases, such as sickle cell 
anemia, paroxysmal nocturnal hemoglobinuria and 
others. In animal models, nonmyeloablative transplan- 
tation has been used to induce tolerance to solid organ 
grafts. 
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The mucosal surface area of an adult individual amounts 
to some 400 m?. This extensive and generally quite 
vulnerable epithelial barrier is protected by numerous 
innate defence mechanisms that cooperate intimately 
with a local adaptive immune system. Its most promin- 
ent feature is an abundance of supepithelial plasma cells 
and B-cell blasts (collectively called immunocytes), 
constituting at least 80% of all antibody-forming cells of 
the body. These local immunocytes produce mainly 
dimeric IgA (dIgA) with incorporated J chain. 
Facing the large host of environmental challenges, 
specific mucosal immunity has developed two strategies: 
(i) immune exclusion performed by secretory antibodies 
(SIgA and SIgM), mainly to inhibit colonization of 
pathogenic microorganisms and penetration of harmful 
antigens; and (ii) immunosuppression to avoid local and 
peripheral hypersensitivity towards innocuous sub- 
stances bombarding the mucosal surfaces. In the gut, the 
latter phenomenon is called oral tolerance; it apparently 
involves several down-regulatory mechanisms and 
explains why most individuals show no adverse immune 
reactions against persistent contact with food proteins 
and the normal microbial flora. 
Immune exclusion depends on an ingenious co- 
operation between the enormous mucosal B-cell system 
and a transmembrane epithelial glycoprotein called 
secretory component (SC), or the polymeric Ig receptor 
(pIgR). This is quantitatively the most important 
receptor of the immune system because it is responsible 
for external transport of large amounts of locally pro- 
duced dIgA and pentameric IgM. The pIgR shows high 
and selective affinity for these two ligands because of 
their incorporated J chain.The epithelial receptor belongs 
to the Ig supergene family and can be upregulated by 
various cytokines, particularly interferon- and inter- 
leukin-4 (IL-4) derived from activated T cells as well as 
IL-1 and TNF- from macrophages. In this way, the 
secretory immune system can be modulated according 
to the intensity of local immune responses. 
During a variable period after birth, both immune 
exclusion and oral tolerance are poorly developed; 
appropriate generation of the underlying network of 
regulatory mechanisms depends both on the establish- 
ment of a normal microbial flora and on the introduction 
of dietary antigens (timing and dose). Breast-feeding 
is immunologically important during this vulnerable 
period, not only as a natural ‘substitution therapy’ for 
the lacking secretory antibodies but apparently also by 
its immune-modulating propertiesThe infant’s secretory 
immune responses are initially dominated by SIgM, but 
after 1 to 2 months SIgA usually predominates, although 
there are large individual variations in the development 
of mucosal immunity. 
Mucosal defence provided by dIgA/SIgA is more 
favourable than that provided by pentameric IgM/SIgM 
because (a) dIgA more easily gains access to the 
basolaterally expressed epithelial pIgR and is therefore 
efficiently transported to the lumen; (b) SIgA is a 
particularly stable antibody class and is therefore well 
suited to perform immune exclusion; (c) dIgA generally 
functions in a noninflammatory manner and may be 
involved in epithelial clearance of soluble antigens from 
the mucosa as well as intraepithelial virus neutralization 
with no cytolytic side-effect; (d) dIgA avidly binds to 
Fc-R on phagocytes and may normally dampen their 
proinflammatory potential but enhance phagocytosis; 
and (e) dIgA and especially SIgA (and SC on a solid 
phase) can efficiently activate eosinophils and thus 
enhance their proinflammatory potential in situations 
where immune exclusion fails, such as in parasitic 
infestations. Our recent construction of pIgR/SC knock- 
out mice has substantiated the importance of secretory 
immunity for mucosal homeostasis and defence against 
toxin-producing pathogens. 
In subjects with IgA deficiency, there is regularly a 
compensatory overproduction of SIgM and IgGl in 
intestinal mucosa; this probably explains why they have 
relatively few problems with gut infections. In contrast, 
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infections are much more common in the respiratory 
tract of IgA-deficient patients, especially in those with 
little or no SIgM compensation in the airways. In patients 
with hypogammaglobulinaemia that virtually lack 
antibody production, a compensatory enhancement of T 
cell-mediated defence by cytotoxic intraepithelial 
lymphocytes (IELs) of the T-cell receptor (TCR)@+ 
CD8+ phenotype apparently takes place. In IgA 
deficiency, such enhancement of cellular mucosal im- 
munity may include both TCRc#+ and TCRy/G+ IELs. 
Interestingly, the number of TCRy/G+ IELs is generally 
increased in AIDS patients, but a short survival 
expectancy (<7 months) is associated with a reduction 
of this subset. 
References 
1 Brandtzaeg, Farstad IN, Johansen F-E, Morton HC, 
Norderhaug IN, Yamanaka T: The B-cell system of human 
mucosae and exocrine glands. Immunol. Rev. 171: 45-87, 
1999. 
2 Brandtzaeg F’, Farstad IN, Helgeland L: Phenotypes of T 
cells in the gut. In: Mucosal T cells (Ed.: MacDonald TT), 
Karger, Basel. Chem. Immunol. 71: l-26,1998. 
3 Brandtzaeg P, Nilssen DE: Mucosal aspects of primary B- 
cell deficiency and gastrointestinal infections. Curr. Opin. 
Gastroenterol. 11: 532-540,1995. 
Infections in diabetics: mechanisms and consequences 
Andy I. M. Hoepelman 
University Medical Center, Department of Medicine, 
Division of Acute Medicine and Infectious Diseases, 
PO Box 85500,3508 GA Utrecht, 
The Netherlands 
There is a general sense among clinicians that people 
with diabetes mellitus (DM) are at increased risk of 
developing infections. The most common of which are 
urinary tract infections (UTI) and skin and soft tissue 
infections usually caused by S. aureus. Moreover, some 
infections occur principally in patients with DM. 
Contrary to common belief, this association is not sup- 
ported by strong epidemiological evidence. A recent 
study (Diabetes Care 2001 24:1044) showed, however, 
that diabetics are at greater risk for infection-related 
mortality which was independent of coexisting heart 
disease at baseline and other diabetes related comor- 
bidities. In contrast to blacks, white men and women are 
more likely to die of pneumonia and influenza 
Although studies show that T-cell function may be 
depressed in patients with DM, most studies point at 
defective innate immunity. It has been shown long ago 
that polymorphonuclear leukocyte (PMN) function is 
depressed when acidosis is present, recent studies do not 
confirm this. There are, however, subtle changes in 
calcium flux but it remains to be proven that these in 
vitro findings have any clinical relevance (FEMS 
Zmmunol Med Microbial 1999;26: 259-65). 
Several studies have assessed the prevalence of 
asymptomatic bacteriuria (ASB) in patients with DM. 
Probably due to selection bias, not discriminating 
between in-and outpatients, and not selecting for 
severity of the underlying disease, there is a wide range 
in prevalence among women (O-29%; mean 20%). We 
recently have completed a study (Diabetes Care 2000; 
23:744-9) in 636 non-pregnant women with DM (in- 
cluding our University Hospital, secondary care hospitals, 
in-and outpatients as well as diabetics visiting their GP). 
The prevalence of ASB was 26% in the diabetic women 
and 6% in the control subjects (P<O.OOl).The prevalence 
of ASB in the 378 women with DM type 2 was 29% 
(compared to 21% in those with DM type 1). Risk 
factors for ASB in type 1 diabetic women included a 
longer duration of diabetes, peripheral neuropathy, and 
macroalbuminuria. The prevalence of ASB was 29% in 
women with type 2 diabetes. Risk factors for ASB in type 
2 diabetic women included age, macroalbuminuria, a 
lower body mass index (BMI), and a UT1 during the 
previous year. No association was evident between 
current HbAlc level and the presence of ASB. 
Follow-up results (Arch Intern Med 2001;161:1421-7) 
were available for 589 (93%) of the 636 women. Of these 
589 women, 115 (20%) (14% with type 1 DM and 23% 
with type 2 DM) developed a symptomatic UTI. Women 
with type 2 DM and ASB at baseline had an increased 
risk of developing a UT1 during the l&month follow-up 
(19% without ASB vs 34% with ASB, P=.OO6). In 
contrast, there was no difference in the incidence of 
symptomatic UT1 between women with type 1 DM and 
ASB and those without ASB (12% with ASB vs 15% 
without ASB). However, women with type 1 DM and 
ASB had a tendency to have a faster decline in renal 
function than those without ASB (relative increase in 
serum creatinine level 4.6% vs 1.5%, P=O.2). We also 
analyzed the risk factors for developing symptomatic 
UT1 (Diabetes Care 2000;23:1737-41). Women with type 
2 DM and ASB have an increased risk of developing a 
symptomatic UT1 than those without ASB. Of the 589 
women, 115 (20%) developed a symptomatic UTI, 96 
(83%) of whom were prescribed antimicrobial therapy. 
A total of 34 women (14%) with type 1 diabetes 
developed a UTI. The most important risk factor for 
these women was sexual intercourse during the week 
before entry into the study (44% without VS. 53% with 
sexual intercourse, relative risk [RR]=3.0, P=O.Ol). A 
total of 81(23%) women with type 2 diabetes developed 
a UTI. The most important risk factor for these women 
was the presence of asymptomatic bacteriuria (ASB) at 
baseline (25% without VS. 42% with ASB, RRx1.65, P= 
0.04). 
Since the regular clinical risk factors were not 
identified as important we also analyzed the role of 
adherence of bacteria to uroepithelial cells of women 
with DM.The number of virulence factors in Escherichia 
co/i isolated from the urine of diabetic women with ASB 
